Cargando…
Recent Progress in the Prevention of Serogroup B Meningococcal Disease
The widespread use of meningococcal polysaccharide conjugate vaccines has highlighted the challenge of providing protection against serogroup B disease. Over a period of 4 decades, vaccine development has focused on subcapsular protein antigens, first with outer membrane vesicle (OMV) vaccines again...
Autores principales: | Feavers, Ian M., Maiden, Martin C. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424234/ https://www.ncbi.nlm.nih.gov/pubmed/28356256 http://dx.doi.org/10.1128/CVI.00566-16 |
Ejemplares similares
-
Molecular epidemiology of meningococcal disease in England and Wales 1975–1995, before the introduction of serogroup C conjugate vaccines
por: Russell, Joanne E., et al.
Publicado: (2008) -
Editorial Commentary: The Endgame for Serogroup A Meningococcal Disease in Africa?
por: Maiden, Martin C. J.
Publicado: (2013) -
FetA Antibodies Induced by an Outer Membrane Vesicle Vaccine Derived from a Serogroup B Meningococcal Isolate with Constitutive FetA Expression
por: Sanders, Holly, et al.
Publicado: (2015) -
Factor H binding protein (fHbp)-mediated differential complement resistance of a serogroup C Neisseria meningitidis isolate from cerebrospinal fluid of a patient with invasive meningococcal disease
por: Facchetti, Alessandra, et al.
Publicado: (2021) -
Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B
por: Rivero-Calle, Irene, et al.
Publicado: (2019)